For: | Ziogas IA, Tsoulfas G. Evolving role of Sorafenib in the management of hepatocellular carcinoma. World J Clin Oncol 2017; 8(3): 203-213 [PMID: 28638790 DOI: 10.5306/wjco.v8.i3.203] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v8/i3/203.htm |
Number | Citing Articles |
1 |
Zhong-Liang Su, Chien-Wei Su, Yi-Luen Huang, Wan-Yu Yang, Bonifasius Putera Sampurna, Toru Ouchi, Kuan-Lin Lee, Chen-Sheng Wu, Horng-Dar Wang, Chiou-Hwa Yuh. A Novel AURKA Mutant-Induced Early-Onset Severe Hepatocarcinogenesis Greater than Wild-Type via Activating Different Pathways in Zebrafish. Cancers 2019; 11(7): 927 doi: 10.3390/cancers11070927
|
2 |
Marta Campos, Isabel Candelária, Nickolas Papanikolaou, Adélia Simão, Carlos Ferreira, Georgios C. Manikis, Filipe Caseiro-Alves. Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study. GE - Portuguese Journal of Gastroenterology 2019; 26(4): 260 doi: 10.1159/000493351
|
3 |
Lingyan Wang, Zhihui Min, Xiangdong Wang, Mushuang Hu, Dongli Song, Zhenggang Ren, Yunfeng Cheng, Yanhong Wang. Arsenic trioxide and sorafenib combination therapy for human hepatocellular carcinoma functions via up‑regulation of TNF‑related apoptosis‑inducing ligand. Oncology Letters 2018; doi: 10.3892/ol.2018.8981
|
4 |
Catia Giovannini, Anna Maria Salzano, Michele Baglioni, Monica Vitale, Andrea Scaloni, Nicola Zambrano, Ferdinando Antonio Giannone, Francesco Vasuri, Antonia D’Errico, Gianluca Svegliati Baroni, Luigi Bolondi, Laura Gramantieri. Brivanib in combination with Notch3 silencing shows potent activity in tumour models. British Journal of Cancer 2019; 120(6): 601 doi: 10.1038/s41416-018-0375-4
|
5 |
J. Aguilar-Company, M. Fernández-Ruiz, R. García-Campelo, A.C. Garrido-Castro, I. Ruiz-Camps. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways). Clinical Microbiology and Infection 2018; 24: S41 doi: 10.1016/j.cmi.2017.12.027
|
6 |
Maria Grazia Lucà, Roberto Nani, Melanie Schranz, Massimo De Giorgio, Claudia Iegri, Roberto Agazzi, Francesco Sala, Giorgio Virotta, Donatella Sarti, Grazia Conte, Domenico Pinelli, Carlo Nicora, Michele Colledan, Sandro Sironi, Stefano Fagiuoli. Treatment of Hepatocellular Carcinoma: A Cost Analysis Of Yttrium-90 Transarterial Radioembolization Versus Sorafenib. Future Oncology 2018; 14(8): 727 doi: 10.2217/fon-2017-0566
|
7 |
Gayathri Karanam, Madan Kumar Arumugam. Potential anticancer effects of cyclo(‐Pro‐Tyr) against N‐diethyl nitrosamine induced hepatocellular carcinoma in mouse through PI3K/AKT signaling. Environmental Toxicology 2022; 37(2): 256 doi: 10.1002/tox.23395
|
8 |
Pompilia Radu, Jean-François Dufour. Changing TACTICS in intermediate HCC: TACE plus sorafenib. Gut 2020; 69(8): 1374 doi: 10.1136/gutjnl-2020-320692
|
9 |
Yang Wang, Liang Ma, Shoupeng Sheng, Zhuhui Yuan, Jiasheng Zheng, Wei Li. Combination therapy of TACE and CT-guided partial hepatic segment ablation for liver cancer. Minimally Invasive Therapy & Allied Technologies 2018; 27(6): 355 doi: 10.1080/13645706.2018.1462833
|
10 |
Kelly Goulart Lima, Gabriele Catyana Krause, Elisa Feller Gonçalves da Silva, Léder Leal Xavier, Léo Anderson Meira Martins, Laura Manzoli Alice, Luiza Bueno da Luz, Rodrigo Benedetti Gassen, Eduardo Cremonese Filippi-Chiela, Gabriela Viegas Haute, Maria Claudia Rosa Garcia, Giselle Afonso Funchal, Leonardo Pedrazza, Camille Kirinus Reghelin, Jarbas Rodrigues de Oliveira. Octyl gallate reduces ATP levels and Ki67 expression leading HepG2 cells to cell cycle arrest and mitochondria-mediated apoptosis. Toxicology in Vitro 2018; 48: 11 doi: 10.1016/j.tiv.2017.12.017
|
11 |
Carla Fernanda Nava, Rafael Selbach Scheffel, Ana Patrícia Cristo, Carla Vaz Ferreira, Shana Weber, André Borsatto Zanella, Francisco Costa Paixão, Alceu Migliavaca, José Ricardo Guimarães, Marcia Silveira Graudenz, José Miguel Dora, Ana Luiza Maia. Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma. Frontiers in Endocrinology 2019; 10 doi: 10.3389/fendo.2019.00712
|
12 |
Bao-Hua Li, Malgorzata A. Garstka, Zong-Fang Li. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor. Molecular Immunology 2020; 117: 201 doi: 10.1016/j.molimm.2019.11.014
|
13 |
Srinivas Pittala, Yakov Krelin, Varda Shoshan-Barmatz. Targeting Liver Cancer and Associated Pathologies in Mice with a Mitochondrial VDAC1-Based Peptide. Neoplasia 2018; 20(6): 594 doi: 10.1016/j.neo.2018.02.012
|
14 |
Yufeng Wang, Zhencun Yang, Liang Wang, Liankang Sun, Zhikui Liu, Qing Li, Bowen Yao, Tianxiang Chen, Cong Wang, Wei Yang, Qingguang Liu, Shaoshan Han. miR-532-3p promotes hepatocellular carcinoma progression by targeting PTPRT. Biomedicine & Pharmacotherapy 2019; 109: 991 doi: 10.1016/j.biopha.2018.10.145
|
15 |
Zhongqiang Zhang, Xiao Tan, Jing Luo, Hongliang Yao, Zhongzhou Si, Jing-Shan Tong. The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma. Cell Death & Disease 2020; 11(10) doi: 10.1038/s41419-020-03123-3
|
16 |
Xiaoyan Ding, Wei Sun, Jinglong Chen. RETRACTED ARTICLE: IL-2 augments the
sorafenib-induced apoptosis in liver cancer by promoting mitochondrial fission and
activating the JNK/TAZ pathway. Cancer Cell International 2018; 18(1) doi: 10.1186/s12935-018-0671-3
|
17 |
Yeonghoon Son, Na-Rae Shin, Sung-Ho Kim, Su-Cheol Park, Hae-June Lee. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells. International Journal of Molecular Sciences 2021; 22(10): 5330 doi: 10.3390/ijms22105330
|
18 |
Alireza Heidari, Sophia Iorgulescu, Olivia Robinson, Lin Hu, Charlotte Vauclin, Ntalie Schiltz, Scarlett Sondermann, Lucy MacLennan, Julia Smith, Lydia Williamson, Alireza Heidari, Sophia Iorgulescu, Olivia Robinson, Lin Hu, Charlotte Vauclin, Ntalie Ntalie Schiltz, Scarlett Sondermann, Lucy MacLennan, Julia Smith, Lydia Williamson, Alireza Heidari, Sophia Iorgulescu, Olivia Robinson, Lydia Williamson, Lin Hu, Charlotte Vauclin, Ntalie Schiltz, Scarlett Sondermann, Lucy MacLennan, Julia Smith, Alireza Heidari, Zahra Torfeh, Xiaoyong Lu. CERN Large Hadron Collider (LHC) Radiation Source for Magnetic Resonance Biospectroscopy in Metabolic and Molecular Imaging and Diagnosis of Cancer. Journal of New Developments in Chemistry 2022; 3(4): 29 doi: 10.14302/issn.2377-2549.jndc-22-4351
|
19 |
Ioannis A. Ziogas, Laura A. Hickman, Lea K. Matsuoka, Manhal Izzy, Martin I. Montenovo, Scott A. Rega, Irene D. Feurer, Sophoclis P. Alexopoulos. Comparison of Wait‐List Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates. Liver Transplantation 2020; 26(9): 1112 doi: 10.1002/lt.25807
|
20 |
Michela Anna Polidoro, Joanna Mikulak, Valentina Cazzetta, Ana Lleo, Domenico Mavilio, Guido Torzilli, Matteo Donadon. Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. World Journal of Gastroenterology 2020; 26(33): 4900-4918 doi: 10.3748/wjg.v26.i33.4900
|
21 |
Grishma R. Trivedi, Shehzad S. Merchant, Tauqeer Hussain Mallhi. Corynebacterium striatum: A True Pathogen in Chronic Contiguous Osteomyelitis. Canadian Journal of Infectious Diseases and Medical Microbiology 2024; 2024: 1 doi: 10.1155/2024/5020721
|
22 |
Lucas Trevisan França de Lima, Daniel Broszczak, Xi Zhang, Kim Bridle, Darrell Crawford, Chamindie Punyadeera. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2020; 1874(2): 188451 doi: 10.1016/j.bbcan.2020.188451
|
23 |
Iman Seyhoun, Saieh Hajighasemlou, Samad Muhammadnejad, Jafar Ai, Mohsen Nikbakht, Ali akbar Alizadeh, Faezeh Hosseinzadeh, Milad Mirmoghtadaei, Seyed Moein Seyhoun, Javad Verdi. Combination therapy of sorafenib with mesenchymal stem cells as a novel cancer treatment regimen in xenograft models of hepatocellular carcinoma. Journal of Cellular Physiology 2019; 234(6): 9495 doi: 10.1002/jcp.27637
|
24 |
Mahmoud A. Younis, Ikramy A. Khalil, Mahmoud M. Abd Elwakil, Hideyoshi Harashima. A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells. Molecular Pharmaceutics 2019; 16(9): 4031 doi: 10.1021/acs.molpharmaceut.9b00738
|
25 |
Carolina Méndez-Blanco, Flavia Fondevila, Paula Fernández-Palanca, Andrés García-Palomo, Jos van Pelt, Chris Verslype, Javier González-Gallego, José Mauriz. Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells. Cancers 2019; 11(12): 1984 doi: 10.3390/cancers11121984
|
26 |
Yusra Zarlashat, Shakil Abbas, Abdul Ghaffar. Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy. Cancers 2024; 16(11): 2034 doi: 10.3390/cancers16112034
|
27 |
Tae Ho Hong, M. T. Jeena, Ok-Hee Kim, Kee-Hwan Kim, Ho Joong Choi, Kyung Hee Lee, Ha-Eun Hong, Ja-Hyoung Ryu, Say-June Kim. Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-resistant hepatocellular carcinoma cells. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-020-79536-z
|
28 |
Mohammad Al-Sanea, Hani Hafez, Ahmed Mohamed, Hamed El-Shafey, Abdullah Elgazar, Samar Tawfik, Wafaa Ewes, Shaimaa Hussein, Tariq Alsahli, Abdelrahman Hamdi. Design, Synthesis, Pharmacological Evaluation of Quinazolin-4(3H)-Ones Bearing Urea Functionality as Potential VEGFR-2 Inhibitors. Drug Design, Development and Therapy 2024; : 5109 doi: 10.2147/DDDT.S490930
|